4369-50-0

Basic information

• Product Name: Methanone, (4-bromophenyl)(4-hydroxyphenyl)-
• CAS NO: 4369-50-0
• Molecular Formula: C13H9BrO2
• Molecular Weight: 277.117
• Mol File: 4369-50-0.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: Methanone, (4-bromophenyl)(4-hydroxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanone, (4-bromophenyl)(4-hydroxyphenyl)-(4369-50-0)
• EPA Substance Registry System: Methanone, (4-bromophenyl)(4-hydroxyphenyl)-(4369-50-0)

Safety Data

• Hazardous Substances Data: 4369-50-0(Hazardous Substances Data)

Upstream product

• 100-66-3 methoxybenzene 
• 586-75-4 4-chlorobenzoyl chloride 
• 54118-75-1 4-bromo-4'-methoxybenzophenone 
• 40292-19-1 (4-aminophenyl)(4-bromophenyl)methanone 
• 766-96-1 4-bromo-1-ethynylbenzene 
• 106-51-4 p-benzoquinone 
• 108-95-2 phenol 
• 192436-83-2 4-bromo-N-methoxy-N-methylbenzamide 

Downstream Products

• 4306-47-2 4-Brom-4'-benzyloxy-benzophenon 

Relevant articles and documents

Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance

Microtubule targeting agents (MTAs) are among the most successful chemotherapeutic drugs, but their efficacy is often limited by the development of multidrug resistance (MDR). Therefore, the development of novel MTAs with the ability to overcome MDR is urgently needed. In this contribution, through modification of the unsymmetric biaryl compounds, we discovered a novel compound dxy-1-175 with potent anti-proliferative activity against cancer cells. Mechanistic study revealed that dxy-1-175 inhibited tubulin polymerization by interacting with the colchicine-binding site of tubulin, which caused cell cycle arrest at G2/M phase. Based on the predicted binding model of dxy-1-175 with tubulin, a series of new 4-benzoylbiphenyl analogues were designed and synthesized. Among them, the hydrochloride compound 12e with improved solubility and good stability in human liver microsome, exhibited the most potent anti-proliferative activity with IC50 value in the low nanomolar range, and markedly inhibited the growth of breast cancer 4T1 xenograft in vivo. Notably, 12e effectively overcame P-gp-mediated MDR and our preliminary data suggested that 12e may not be a substrate of P-glycoprotein (P-gp). Taken together, our study reveals a novel MTA 12e targeting the colchicine-binding site with potent anticancer activity and the ability to circumvent MDR.

NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to an aryl ethene derivative, for inhibiting an estrogen-related receptor gamma (ERRγ) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, and a pharmaceutical

NOVEL ARYL ETHENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to an aryl ethene derivative represented by chemical formula 1 which suppresses the activity of estrogen-related receptor gamma (ERRandgamma;), a prodrug thereof, a solvate thereof, a stereomer thereof, or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition comprising the same as an effective component. In the chemical formula 1, R^1, R^2, L and Ar are the same as defined in the detailed description of the invention.COPYRIGHT KIPO 2018